Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared a post by Parker Institute for Cancer Immunotherapy on LinkedIn, adding:
“When two organizations committed to curing cancer come together, the impact is all the greater. We at Parker Institute for Cancer Immunotherapy are beyond proud to partner with American Society of Clinical Oncology (ASCO) to ensure that there will always be funding for early-career investigators focused on breakthrough therapeutics.
Our combined goal is clear… cancer cures, faster!”
Quoting Parker Institute for Cancer Immunotherapy‘s post:
“We’re excited to announce a new collaboration with American Society of Clinical Oncology (ASCO) to co-fund a Conquer Cancer, the ASCO Foundation, Endowed Young Investigator Award (YIA) to support the next generation of cancer immunotherapy leaders.
Through PICI’s commitment, the Endowed Young Investigator Award (YIA) will provide a $50,000 annual grant to fund early-career oncologists advancing high-quality immunotherapy research and clinical discovery.
PICI CEO Karen Knudsen MBA PhD sat down with Clifford Hudis, CEO of ASCO and executive vice chair of Conquer Cancer, to discuss why sustained investment in emerging investigators is critical to accelerating breakthrough therapies.
Together, we’re helping build the next wave of transformative cancer treatments.
Read more on the news. Watch below.”
More posts featuring Karen Knudsen on OncoDaily.